Report Content
Chapter 1 Methodology & Scope
1.1 Market definitions
1.2 Base estimates and calculations
1.3 Forecast calculations
1.4 Data Validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Public sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 U.S. Peptide therapeutics industry 3600 synopsis, 2018 – 2032 (USD Billion)
2.1.1 Business trends
2.1.2 Type trends
2.1.3 Application trends
2.1.4 Route of administration trends
2.1.5 Manufacturer type trends
2.1.6 Synthesis technology trends
2.1.7 Distribution channel trends
2.1.8 Region trends
Chapter 3 U.S. Peptide Therapeutics Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Billion)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of cancer in the U.S.
3.2.1.2 Rising incidences of metabolic disorders
3.2.1.3 Increasing investments in R&D of novel drugs
3.2.1.4 Technological advancement in peptide therapeutics
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory requirements for drug approval
3.2.2.2 High cost for drug development
3.3 Growth potential analysis
3.3.1 By type
3.3.2 By application
3.3.3 By route of administration
3.3.4 By manufacturer type
3.3.5 By synthesis technology
3.3.6 By distribution channel
3.4 COVID-19 impact analysis
3.5 Clinical trial analysis
3.6 Technology analysis
3.7 Regulatory landscape
3.8 Porter’s analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive positioning matrix, 2022
4.4 Strategic dashboard, 2022
Chapter 5 U.S. Peptide Therapeutics Market Estimates and Forecast, By Type, 2018-2032 (USD Billion)
5.1 Key trends, by type
5.2 Branded peptides
5.3 Generic peptides
Chapter 6 U.S. Peptide Therapeutics Market Estimates and Forecast, By Application, 2018-2032 (USD Billion)
6.1 Key trends, by application
6.2 Metabolic and endocrine disorders
6.3 Cancer
6.4 Cardiovascular disorders
6.5 Gastrointestinal disorders
6.6 Central nervous system disorders
6.7 Respiratory disorders
6.8 Pain management
6.9 Renal disorders
6.10 Dermatology
6.11 Other applications
Chapter 7 U.S. Peptide Therapeutics Market Estimates and Forecast, By Route of Administration, 2018-2032 (USD Billion)
7.1 Key trends, by route of administration
7.2 Parenteral
7.3 Oral
7.4 Other routes of administration
Chapter 8 U.S. Peptide Therapeutics Market Estimates and Forecast, By Manufacturer Type, 2018-2032 (USD Billion)
8.1 Key trends, by manufacturer type
8.2 In-house
8.3 Outsourced
Chapter 9 U.S. Peptide Therapeutics Market Estimates and Forecast, By Synthesis Technology, 2018-2032 (USD Billion)
9.1 Key trends, by synthesis technology
9.2 Liquid phase peptide synthesis (LPPS)
9.3 Solid phase peptide synthesis (SPPS)
9.4 Hybrid Technology
Chapter 10 U.S. Peptide Therapeutics Market Estimates and Forecast, By Distribution Channel, 2018-2032 (USD Billion)
10.1 Key trends, by distribution channel
10.2 Hospital pharmacies
10.3 Retail pharmacies
10.4 Online pharmacies
Chapter 11 Company Profiles
11.1 Pfizer, Inc
11.2 Amgen, Inc
11.3 Eli Lilly and Company
11.4 Sanofi SA
11.5 AstraZeneca
11.6 AbbVie, Inc.
11.7 GlaxoSmithKline plc
11.8 Baush Health Companies Inc.
11.9 Sun Pharmaceutical Industries Ltd.
11.10 Novo Nordisk
